대한한방소아과학회지 (The Journal of Pediatrics of Korean Medicine)

  • 제35권3호
  • /
  • Pages.128-137
  • /
  • 2021
  • /
  • 1226-8038(pISSN)
  • /
  • 2287-9463(eISSN)
대한한방소아과학회 (The Association of Korean Oriental Pediatrics)
권호 표지
DOI QR코드

DOI QR Code

황련추출물-ceramide 복합물의 지방장벽 형성 조절을 통한 상피 염증 완화 효과

Effect of Epithelial Inflammation Relief through Regulation of Lipid Barrier Formation of Coptidis Rhizoma Extract-Ceramide Complex

  • 안상현 (세명대학교 한의과대학 해부학교실) ;
  • 김기봉 (부산대학교 한의학전문대학원)
  • Ahn, Sang Hyun (Dept. of anatomy, college of Korean Medicine, Semyung University) ;
  • Kim, Ki Bong (School of Korean Medicine, Pusan National University)
  • 투고 : 2021.07.23
  • 심사 : 2021.08.23
  • 발행 : 2021.08.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objective The purpose of this study was to confirm the effectiveness of coptidis rhizoma extract-ceramide complex on skin barrier, transepidermal water loss (TEWL) and pH reduction, and inflammation of the skin. Methods Coptidis rhizoma extract-ceramide complex was applied in 6-week-old Balb/C mice after dermatitis was induced. To confirm the skin condition changes, TEWL and pH were observed, and filaggrin in the stratum corneum of the skin was observed. Kallikrein-related peptidase (KLK) 7, Protease activated receptor (PAR)-2, Thymic stromal lymphopoietin (TSLP), and IL-4 were observed in the stratum corneum to confirm the changes in the inflammatory response. Results Filaggrin positive reaction was increased in the experiment group compared to the control group. TEWL and pH were lower in the experiment group compared to the control group. KLK7, PAR2, TSLP, and IL-4 positive responses were decreased in the experiment group compared to the control group. Conclusions It was confirmed that the coptidis rhizoma extract-ceramide complex can relieve the inflammatory response of atopic dermatitis by restoring the skin lipid barrier damage.

키워드

과제정보

이 연구는 2019년도 정부의 재원으로 한국연구재단의 지원을 받아 수행된 기초연구사업임 (No. NRF-2019R1A2C1002443).

참고문헌

  1. Kim YJ, Ahn JY, Seo SJ, Hong CK. The effect of retinoic acid on expression of human beta defensin-2 and LL-37 in keratinocyte. J Korean Invest Dermatol. 2007;14:29-35.
  2. Kwon MS, Choi TB, Kim GY. The effect on the skin barrier function of ceramide. Kor J Aesthet Cosmetol. 2005;3(1):131-7.
  3. Yoon YM, Yoon JY, Lim KM, Hahn HJ, Kim YR, Ahn KJ, An SK. Effects of the complex containing Centella asiatica-and folic acid-fermented extracts, acetyl glutamine, and nicotinic acid adenine dinucleotide phosphate on the inhibition of senescence and elanogenesis, promotion of collagen expression, cellular regeneration, and keratinocyte differentiation, and anti-inflammation. Kor J Aesthet Cosmetol. 2013;11(4):675-84.
  4. Steinert PM, Marekov LN. The proteins elafin, filaggrin, keratin intermediate filaments, loricrin, and small proline-rich proteins 1 and 2 are isodipeptide cross-linked components of the human epidermal cornified cell envelope. J Biol Chem. 1995;270(30):17702-11. https://doi.org/10.1074/jbc.270.30.17702
  5. Steven AC, Steinert PM. Protein composition of cornified cell envelopes of epidermal keratinocytes. J Cell Sci. 1994;107(2):693-700. https://doi.org/10.1242/jcs.107.2.693
  6. Elias PM, Menon GK. Structural and lipid biochemical correlates of the epidermal permeability barrier. Adv Lipid Res. 1991;24:1-26. https://doi.org/10.1016/B978-0-12-024924-4.50005-5
  7. Steinert PM, Cantieri JS, Teller DC, Lonsdale-Eccles JD, Dale BA. Characterization of a class of cationic proteins that specifically interact with intermediate filaments. Proc Natl Acad Sci USA. 1981;78(7):4097-101. https://doi.org/10.1073/pnas.78.7.4097
  8. Cornelissen C, Marquardt Y, Czaja K, Wenzel J, Frank J, Luscher-Firzlaff J, Luscher B, Baron J. IL-31 regulates differentiation and filaggrin expression in human organotypic skin models. J Allergy Clin Immunol. 2012;129(2):426-33. https://doi.org/10.1016/j.jaci.2011.10.042
  9. Irvine AD, McLean WH. Breaking the (un)sound barrier: filaggrin is a major gene for atopic dermatitis. J Invest Dermatol. 2006;126(6):1200-2. https://doi.org/10.1038/sj.jid.5700365
  10. Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, Goudie DR, Sandilands A, Campbell LE, Smith FJ, O'Regan GM, Watson RM, Cecil JE, Bale SJ, Compton JG, DiGiovanna JJ, Fleckman P, Lewis-Jones S, Arseculeratne G, Sergeant A, Munro CS, Houate BE, McElreavey K, Halkjaer LB, Bisgaard H, Mukhopadhyay S, McLean WH. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006;38(4):441-6. https://doi.org/10.1038/ng1767
  11. O'Regan GM, Irvine AD. The role of filaggrin in the atopic diathesis. Clin Exp Allergy. 2010;40:965-72. https://doi.org/10.1111/j.1365-2222.2010.03522.x
  12. Barnes KC. An update on the genetics of atopic dermatitis: scratching the surface in 2009. J Allergy Clin Immunol. 2010;125(1):16-29. https://doi.org/10.1016/j.jaci.2009.11.008
  13. Kim BB, Kim JR, Kim JH, Kim YA, Park JS, Yeom MH, Lee HJ, Lee KW, Kang NJ. 7,3',4'-Trihydroxyisoflavone ameliorates the development of Dermatophagoides farinae-induced atopic dermatitis in NC/Nga Mice. Evid-Based Complement Alternat Med. 2013;2013:636597
  14. Weidinger S, Novak N. Atopic dermatitis. Lancet (London, England). 2016;387(10023):1109-22. https://doi.org/10.1016/S0140-6736(15)00149-X
  15. Kim JH. Current understanding of atopic dermatitis. Pediatr Allergy Respir Dis. 2004;14(1):12-23.
  16. Boguniewicz M. Atopic dermatitis: the updated practice parameter and beyond. Allergy Asthma Proc. 2014;35(6):429-34. https://doi.org/10.2500/aap.2014.35.3798
  17. Kim BE, Leung D. Epidermal barrier in atopic dermatitis. Immunol Res. 2012;4(1):12-6.
  18. Hogan MB, Peele K, Wilson NW. Skin barrier function and its importance at the start of the atopic march. J Allergy (Cairo). 2012;2012:901940. https://doi.org/10.1155/2012/901940
  19. Boguniewicz M, Eichenfield LF, Hultsch T. Current management of atopic dermatitis and interruption of the atopic march. J Allergy Clin Immunol. 2003;112(6):140-50.
  20. Im GM, Kim HJ, Jeong WY, Jeong HW. Oriental medical approach on the allergic disease. Korea J Oriental Physiology & Pathology. 2002;16(5):831-9.
  21. Cha HY, Ahn SH, Cheon JH, Park SY, Kim KB. Hataedock treatment has preventive therapeutic effects for atopic dermatitis through skin barrier protection in Dermatophagoides farinae-induced NC/Nga mice. J Ethnopharmacol. 2017;206:327-36. https://doi.org/10.1016/j.jep.2017.06.001
  22. Muluye RA, Bian Y, Alemu PN. Anti-inflammatory and antimicrobial effects of heat-clearing Chinese herbs: a current review. J Tradit Complement Med. 2014;4(2):93-8. https://doi.org/10.4103/2225-4110.126635
  23. Tang J, Feng YB, Tsao S, Wang N, Curtain R, Wang YW. Berberine and Coptidis Rhizoma as novel antineoplastic agents: a review of traditional use and biomedical investigations. J Ethnopharmacol 2009;126(1):5-17. https://doi.org/10.1016/j.jep.2009.08.009
  24. Chin LW, Cheng YW, Lin SS, Lai YY, Lin LY, Chou MY, Chou MC, Yang CC. Anti-herpes simplex virus effects of berberine from Coptidis Rhizoma, a major component of a Chinese herbal medicine, Ching-Wei-San. Arch Virol 2010;155(12):1933-41. https://doi.org/10.1007/s00705-010-0779-9
  25. Yu YE, Park EY, Jung DH, Byun SH, Kim SC, Park SM. Antibacterial activity of oriental medicinal herb extracts against skin pathogens. J Life Sci. 2010;20(7):1143-50. https://doi.org/10.5352/JLS.2010.20.7.1143
  26. Jabbarzadeh Kaboli P, Rahmat A, Ismail P, Ling KH. Targets and mechanisms of berberine, a natural drug with potential to treat cancer with special focus on breast cancer. Eur J Pharmacol 2014;740:584-95. https://doi.org/10.1016/j.ejphar.2014.06.025
  27. Ortiz LM, Lombardi P, Tillhon M, Scovassi AI. Berberine, an epiphany against cancer. Molecules. 2014;19(8):12349-67. https://doi.org/10.3390/molecules190812349
  28. Yu M, Tong X, Qi B, Qu H, Dong S, Yu B. Berberine enhances chemosensitivity to irinotecan in colon cancer via inhibition of NFkappaB. Mol Med Rep. 2014;9(1):249-54. https://doi.org/10.3892/mmr.2013.1762
  29. Kim HK, Hong SU. The anti-inflammatory effects of Huang-Lyun (Coptidis Rhizoma, CR) on injured tissue after burn elicitation. J Korean Oriental Med. 2011;32(2):1-13.
  30. Forslin, B. A domain mosaic model of the skin barrier. Acta Derrn Venereol. 1994;74(1):1-6.
  31. Mohsenzadeh M. Evaluation of antibacterial activity of selected Iranian essential oils against Staphylococcus aureus and Escherichia coli in nutrient broth medium. Pak J Biol Sci. 2007;10(20):3693-7. https://doi.org/10.3923/pjbs.2007.3693.3697
  32. Rasul A, Akhtar N, Khan BA, Mahmood T, Uz Zaman S, Khan HM. Formulation development of a cream containing fennel extract: in vivo evaluation for anti-aging effects. Pharmazie. 2012;67(1);54-8.
  33. Yu HY, Yang IJ, Lincha VR, Park IS, Lee DU, Shin HM. The effects of the fruits of Foeniculum vulgare on skin barrier function and hyaluronic acid production in HaCaT Keratinocytes. J Life Sci. 2015;25(8):880-8. https://doi.org/10.5352/JLS.2015.25.8.880
  34. Van Smeden J, Bouwstra JA. Stratum Corneum lipids: their role for the skin barrier function in healthy subjects and atopic dermatitis patients. Curr Probl Dermatol. 2016;49:8-26. https://doi.org/10.1159/000441540
  35. Steinert PM, Marekov LN. The proteins elafin, filaggrin, keratin intermediate filaments, loricrin, and small proline-rich proteins 1 and 2 are isodipeptide cross-linked components of the human epidermal cornified cell envelope. J Biol Chem. 1995;270(30):17702-11. https://doi.org/10.1074/jbc.270.30.17702
  36. Kwon YB, Choi DK, Sohn KC, Jeon EK, Nam MS, Lee JH, Kim CD. Effects of colostrum on keratinocyte differentiation and wound healing. Kor J Invest Dermatol. 2007;14(2):45-50.
  37. Smith FJ, Palmer CN, Irvine AD, Terron-Kwiatkowski A, Sandilands A, Campbell LE, Zhao Y, Liao H, Evans AT, Goudie DR, Jones SL, Arseculeratne G, Munro CS, Sergeant A, O'Regan G, Bale SJ, Compton JG, DiGiovanna JJ, Presland RB, Fleckman P, McLean WH. Loss of function mutations in the geneencoding filaggrin cause ichthyosis vulgaris. Nat Genet. 2006;38(3):337-42. https://doi.org/10.1038/ng1743
  38. O'Regan GM, Irvine AD. The role of filaggrin in the atopic diathesis. Clin Exp Allergy. 2010;40:965-972. https://doi.org/10.1111/j.1365-2222.2010.03522.x
  39. Elias PM, Steinhoff M. "Outside-to-Inside" (and now back to "Outside") pathogenic mechanisms in atopic dermatitis. J Invest Dermatol. 2008; 128(5):1067-70. https://doi.org/10.1038/jid.2008.88
  40. Kim BE, Donald YM, Boguniewicz M, Michael DH. Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6. Clin Immunol. 2008;126(3):332-7. https://doi.org/10.1016/j.clim.2007.11.006
  41. Hatano Y, Terashi H, Arakawa S, Katagiri K. Interleukin-4 suppresses the enhancement of ceramide synthesis and cutaneous permeability barrier functions induced by tumor necrosis factor-alpha and interferon-gamma in human epidermis. J Invest Dermatol. 2005;124(4):786-92. https://doi.org/10.1111/j.0022-202X.2005.23651.x
  42. Albanesi C, Fairchild HR, Madonna S, Scarponi C, Pita OD, Leung DY, Howell MD. IL-4 and IL-13 negatively regulate TNF-alpha- and IFN-gamma induced beta-defensin expression through STAT-6, suppressor of cytokine signaling (SOCS)-1, and SOCS-3. J Immunol. 2007;179(2):984-92. https://doi.org/10.4049/jimmunol.179.2.984
  43. Proksch E, Brandner JM, Jensen JM. The skin: an indispensable barrier. Exp Dermatol. 2008;17(12):1063-72. https://doi.org/10.1111/j.1600-0625.2008.00786.x
  44. Baroni A, Buommino E, De Gregorio V, Ruocco E, Ruocco V, Wolf R. Structure and function of the epidermis related to barrier properties. Clin Dermatol. 2012;30(3):257-62. https://doi.org/10.1016/j.clindermatol.2011.08.007
  45. Rippke F, Schreiner V, Doering T, Maibach HI. Stratum corneum pH in atopic dermatitis: impact on skin barrier function and colonization with Staphylococcus Aureus. Am J Clin Dermatol. 2004;5(4):217-23. https://doi.org/10.2165/00128071-200405040-00002
  46. Choi EH, Yoon NY. Pathogenesis of atopic dermatitis. J Korean Med Assoc 2014;57(3):218-25. https://doi.org/10.5124/jkma.2014.57.3.218
  47. Kim HJ, Lee SH. The effect of skin surface on epidermal permeability barrier. J Skin Barrier Res. 2008;10(1):44-55.
  48. Chen JQ, Liang BH, Li HP, Mo ZY, Zhu HL. Roles of kallikrein-related peptidase in epidermal barrier function and related skin diseases. Int J Dermatol Venereol. 2019;2(3):150-5. https://doi.org/10.1097/JD9.0000000000000036
  49. Yamamoto M, Miyai M, Matsumoto Y, Tsuboi R, Hibino T. Kallikrein-related peptidase-7 regulates caspase-14 maturation during keratinocyte terminal differentiation by generating an intermediate form. J Biol Chem. 2012;287(39):32825-34. https://doi.org/10.1074/jbc.M112.357467
  50. Ahn SH, Kim JK, Cheon JH, Kim KB. The effect of Douchi Hataedock treatment for Dermatophagoides farinae-induced atopic dermatitis-like skin lesions by controlling IL-4 activity. J Pediatr Korean Med. 2017;31(1):43-51. https://doi.org/10.7778/jpkm.2017.31.1.043
  51. Li S, Zhang ZQ, Wu LJ, Zhang XG, Li YD, Wang YY. Understanding ZHENG in traditional Chinese medicine in the context of neuro-endocrine-immune network. IET Syst Biol. 2007;1(1):51-60. https://doi.org/10.1049/iet-syb:20060032
  52. Cha HY, Ahn SH, Cheon JH, Park SY, Choi JY, Kim KB. Anti-inflammatory effects of Hataedock extracted from Coptidis Rhizoma and Glycyrrhiza Uralensis on atopic dermatitis-like skin lesions of NC/Nga Mouse. J Int Korean Med. 2015;36(4):486-97.
  53. Fu S, Ni S, Wang D, Hong T. Coptisine suppresses mast cell degranulation and ovalbumin-induced allergic rhinitis. Molecules. 2018;23(11):3039 https://doi.org/10.3390/molecules23113039